CL2023001061A1 - Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación. - Google Patents

Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación.

Info

Publication number
CL2023001061A1
CL2023001061A1 CL2023001061A CL2023001061A CL2023001061A1 CL 2023001061 A1 CL2023001061 A1 CL 2023001061A1 CL 2023001061 A CL2023001061 A CL 2023001061A CL 2023001061 A CL2023001061 A CL 2023001061A CL 2023001061 A1 CL2023001061 A1 CL 2023001061A1
Authority
CL
Chile
Prior art keywords
indol
pyrazole
cyano
isopropyl
carboxylic acid
Prior art date
Application number
CL2023001061A
Other languages
English (en)
Inventor
Seok Cheol Yoo
Joomyung Jang
Ree Sun Kim
Jin A Seo
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of CL2023001061A1 publication Critical patent/CL2023001061A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una formulación oral que comprende un API seleccionado de ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable de este en un alto contenido. Debido a que la formulación oral según la presente invención tiene un alto contenido y excelentes propiedades físicas al comprender un fluidificante en los excipientes, se puede incrementar la eficiencia económica y la conveniencia de la administración.
CL2023001061A 2020-12-01 2023-04-13 Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación. CL2023001061A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20200165790 2020-12-01

Publications (1)

Publication Number Publication Date
CL2023001061A1 true CL2023001061A1 (es) 2023-12-11

Family

ID=81854229

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023001061A CL2023001061A1 (es) 2020-12-01 2023-04-13 Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación.

Country Status (16)

Country Link
US (1) US20240173259A1 (es)
EP (1) EP4257124A4 (es)
JP (2) JP7618806B2 (es)
KR (1) KR102749901B1 (es)
CN (1) CN116528853B (es)
AR (1) AR124180A1 (es)
AU (1) AU2021392532B2 (es)
BR (1) BR112023009427A2 (es)
CA (1) CA3195598A1 (es)
CL (1) CL2023001061A1 (es)
CO (1) CO2023005206A2 (es)
MX (1) MX2023005461A (es)
PE (1) PE20230850A1 (es)
TW (1) TWI884340B (es)
WO (1) WO2022119270A1 (es)
ZA (1) ZA202305155B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3197405A1 (en) * 2020-12-01 2022-06-09 Lg Chem, Ltd. Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl) pyrazole-4-carboxylic acid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20070014853A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Pharmaceutical dosage form containing novel pharmaceutical granulate
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
US8003647B2 (en) * 2007-04-11 2011-08-23 Kissei Pharmaceutical Co., Ltd. (Aza)indole derivative and use thereof for medical purposes
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
CA2813555C (en) * 2010-10-15 2014-11-25 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
TWI548630B (zh) 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
WO2013001441A1 (en) * 2011-06-29 2013-01-03 Ranbaxy Laboratories Limited Dry formulations of febuxostat
EP2692342A1 (en) * 2012-07-30 2014-02-05 Interquim, S.A. Process for the preparation of pharmaceutical compositions comprising febuxostat in the form of tablets
US10064826B2 (en) * 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
JP2017081859A (ja) * 2015-10-29 2017-05-18 共和薬品工業株式会社 テルミサルタン含有錠剤の製造方法
CN106880619A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种托匹司他胶囊剂及其制备方法
JP6946609B2 (ja) * 2017-06-08 2021-10-06 高田製薬株式会社 ブロナンセリン含有錠剤
JP2020117503A (ja) * 2019-01-25 2020-08-06 株式会社東洋新薬 経口組成物
EP4218755A4 (en) * 2020-11-04 2024-03-27 Lg Chem, Ltd. METHOD FOR PRODUCING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBONIC ACID AND PHARMACEUTICAL COMPOSITION THEREFROM

Also Published As

Publication number Publication date
JP2025039725A (ja) 2025-03-21
EP4257124A1 (en) 2023-10-11
EP4257124A4 (en) 2024-05-29
CA3195598A1 (en) 2022-06-09
US20240173259A1 (en) 2024-05-30
AR124180A1 (es) 2023-02-22
JP7618806B2 (ja) 2025-01-21
AU2021392532A1 (en) 2023-06-29
PE20230850A1 (es) 2023-05-23
KR102749901B1 (ko) 2025-01-03
WO2022119270A1 (ko) 2022-06-09
MX2023005461A (es) 2023-05-22
BR112023009427A2 (pt) 2024-02-06
CN116528853B (zh) 2026-03-20
CN116528853A (zh) 2023-08-01
TW202231270A (zh) 2022-08-16
ZA202305155B (en) 2024-09-25
TWI884340B (zh) 2025-05-21
JP2023551524A (ja) 2023-12-08
AU2021392532B2 (en) 2025-04-10
CO2023005206A2 (es) 2023-04-27
KR20220077092A (ko) 2022-06-08

Similar Documents

Publication Publication Date Title
CL2025000823A1 (es) Compuesto de anillo fusionado con pirimidina, y su método de preparación y uso
MX2022007350A (es) Derivados de pirazolilo utiles como agentes anticancerigenos.
PH12019502052A1 (en) Hepatitis b virus surface antigen inhibitor
CN113412260A (zh) 己酮糖激酶抑制剂及其用途
PH12022550338A1 (en) 2-hydroxycycloalkane-1-carbamoyl derivatives
MX2020003421A (es) Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
ZA202403360B (en) Lipid nanoparticles for oligonucleotide delivery
ZA202403337B (en) Lipid nanoparticles for oligonucleotide delivery
SA522431777B1 (ar) مشتقات ألفا -d- جالاكتو بيرانوسيد
UA116053C2 (uk) Застосування похідних бензоімідазолу-проліну
MX2023005039A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3.
CL2023001061A1 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación.
MX2022001743A (es) Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
CO2023008265A2 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico y un proceso para su preparación
AR119061A1 (es) CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE SCAP Y MÉTODOS DE USO DE LAS MISMAS
WO2025036472A8 (en) Spirocyclic mta-cooperative prmt5 inhibitor
AR127165A1 (es) Resmetirom para reducir el volumen del hígado
MX2021012392A (es) Compuestos, composiciones y metodos.
AR125366A1 (es) Formulación compuesta para administración oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
CL2023003571A1 (es) Formulación compuesta para dosificación oral que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico
DOP2021000028A (es) Formulaciones de dendrímeros
AR086184A1 (es) Procedimiento de preparacion de un producto de plasma deplecionado de uno o varios factores trombogenicos
MX2020013574A (es) Composicion farmaceutica para la administracion oral que comprende un inhibidor de la bomba de protones con absorcion mejorada.
AR133855A1 (es) Compuestos de amina sustituida, composiciones y métodos de uso